SISaba Ilkhani

Saba Ilkhani

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Saba Ilkhani has a total of 183 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Socioeconomic and geographic variation in response to trauma medical home intervention

    by Saba Ilkhani, Malaz Boustani, Emma Holler, Damaris Ortiz, Anthony Perkins, Sujuan Gao, Babar Khan, Ben L. Zarzaur

    BACKGROUND: Many injury survivors experience persistent biopsychosocial morbidity after hospital discharge. The trauma medical home (TMH), a multidisciplinary coordinated care model, demonstrated modest benefit in a multicenter randomized trial, but its effectiveness across rural and socioeconomically deprived populations remains unclear. METHODS: This post hoc retrospective analysis of the TMH parent randomized trial included patients aged older than or equal to 50 years with an Injury Severity Score ≥9 across four level I trauma centers. For this study, patients were categorized by rurality and Area Deprivation Index (ADI). Outcomes included the SF-36 Physical and Mental Component Scores (PCS, MCS), depression [Patient Health Questionnaire-9 (PHQ-9)], anxiety [Generalized Anxiety Disorder (GAD-7)], physical function [Short Physical Performance Battery (SPPB)], and health care utilization. Interaction effects between TMH and rural/urban status or ADI were evaluated at baseline, 6 months, and 12 months RESULTS: Four hundred thirty patients were included [216 TMH and 214 in usual care (UC)]. On the basis of urbanicity, the effectiveness of TMH on quality of life, psychological, physical, and health care utilization was similar at 6 and 12 months. ADI stratification showed greater differences. In high-ADI urban areas, baseline MCS scores were similar between TMH (47.5 ± 13.0) and UC (48.6 ± 12.8). By 6 months, TMH patients improved to 54.9 ± 8.8 compared with 49.0 ± 13.1 in UC, with a predicted difference of 7.7 (95% CI: 1.32, 12.83, P =0.016), demonstrating a clinically and statistically significant benefit of TMH CONCLUSIONS: The TMH was associated with greater mental health improvement among patients with high area deprivation, particularly in urban settings, suggesting a potential role in reducing disparities through coordinated care. LEVEL OF EVIDENCE: Prognostic and Epidemiological; Level III

  • Social support can mitigate socioeconomic disparities in trauma patients

    by S. Ilkhani, C.K. Zogg, I.G. Alty, D. Scantling, N. Pinkes, M. Castillo-Angeles, S.E. Sanchez, J.O. Hwabejire, W. Rafaqat, A. Salim, et al.


  • The impact of frailty on long-term functional outcomes in severely injured geriatric patients

    by Wardah Rafaqat, Vahe S. Panossian, May Abiad, Karen Ghaddar, Saba Ilkhani, Ben Grobman, Juan P. Herrera-Escobar, Ali Salim, Geoffrey A. Anderson, Sabrina Sanchez, et al.


  • Examining nonmilitary and nongovernmental humanitarian surgical capacity and response in armed conflicts: A scoping review of the recent literature

    by Mayte Bryce-Alberti, Michelle Bosché, Ryan Benavente, Aulina Chowdhury, Lili B. Steel, Kiana Winslow, Paul A. Bain, Thalia Le, Radzi Hamzah, Saba Ilkhani, et al.


  • Determinants of long-term physical and mental health outcomes after intensive care admission for trauma survivors

    by Juan P. Herrera-Escobar, Taylor Lamarre, Jordan Rosen, Saba Ilkhani, Ashley N. Haynes, Kaman Hau, Kendall Jenkins, Jack Ruske, Joyce Y. Wang, Jessica Serventi-Gleeson, et al.


  • The invisible scars: Unseen financial complications worsen every aspect of long-term health in trauma survivors

    by Saba Ilkhani, Abbie E. Naus, Nathaniel Pinkes, Wardah Rafaqat, Ben Ba Grobman, Madeline D. Ba Valverde, Sabrina E. Sanchez, John O. Md Hwabejire, Kavitha Ranganathan, John W. Scott, et al.

    BACKGROUND: Trauma survivors are susceptible to experiencing financial toxicity (FT). Studies have shown the negative impact of FT on chronic illness outcomes. However, there is a notable lack of data on FT in the context of trauma. We aimed to better understand prevalence, risk factors, and impact of FT on trauma long-term outcomes. METHODS: Adult trauma patients with an Injury Severity Score (ISS) ≥9 treated at Level I trauma centers were interviewed 6 months to 14 months after discharge. Financial toxicity was considered positive if patients reported any of the following due to the injury: income loss, lack of care, newly applied/qualified for governmental assistance, new financial problems, or work loss. The Impact of FT on Patient Reported Outcome Measure Index System (PROMIS) health domains was investigated. RESULTS: Of 577 total patients, 44% (254/567) suffered some form of FT. In the adjusted model, older age (odds ratio [OR], 0.4; 95% confidence interval [95% CI], 0.2–0.81) and stronger social support networks (OR, 0.44; 95% CI, 0.26–0.74) were protective against FT. In contrast, having two or more comorbidities (OR, 1.81; 95% CI, 1.01–3.28), lower education levels (OR, 1.95; 95% CI, 95%, 1.26–3.03), and injury mechanisms, including road accidents (OR, 2.69; 95% CI, 1.51–4.77) and intentional injuries (OR, 4.31; 95% CI, 1.44–12.86) were associated with higher toxicity. No significant relationship was found with ISS, sex, or single-family household. Patients with FT had worse outcomes across all domains of health. There was a negative linear relationship between the severity of FT and worse mental and physical health scores. CONCLUSION: Financial toxicity is associated with long-term outcomes. Incorporating FT risk assessment into recovery care planning may help to identify patients most in need of mitigative interventions across the trauma care continuum to improve trauma recovery. Further investigations to better understand, define, and address FT in trauma care are warranted. LEVEL OF EVIDENCE: Prognostic and Epidemiological; Level III.


  • Open Access

    Association of Seizure with COVID-19 Vaccines in Persons with Epilepsy: A Systematic Review and Meta-analysis

    by Ali Rafati, Melika Jameie, Mobina Amanollahi, Mana Jameie, Yeganeh Pasebani, Delaram Sakhaei, Saba Ilkhani, Sina Rashedi, Mohammad Yazdan Pasebani, Mohammadreza Azadi, et al.

    Objective: Seizure following immunization, especially in persons with epilepsy (PwE), has long been a concern, and seizure aggravation followed by Coronavirus Disease 2019 (COVID-19) vaccines is a serious issue for PwE. The immunization rate in PwE has been lower compared to same-age controls due to vaccine hesitancy and concerns about seizure control. Herein, we systematically reviewed the seizure activity-related events in PwE following COVID-19 vaccination. Methods: Four search engines were searched from inception until January 31, 2023, and the Preferred Reporting Items for Systematic Reviews and Meta-Analyses was followed. Random- and fixed-effect models using the logit transformation method were used for meta-analysis. The quality of the studies was evaluated by the Newcastle-Ottawa scale. Outcomes of interest included (a) pooled proportion of increased seizure frequency and (b) pooled incidence proportion of status epilepticus (SE) in PwE receiving COVID-19 vaccines. Results: Of the 2207 studies identified, 18 met eligibility criteria, of which 16 entered the meta-analysis. The pooled proportion of increased seizure frequency (16 studies-4197 PwE) was 5% (95CI: 3%-6%, I 2 =57%), further subcategorized into viral vector (3%, 95CI: 2%-7%, I 2 =0%), mRNA (5%, 95CI: 4%-7%, I 2 =48%), and inactivated (4%, 95CI: 2%-8%, I 2 =77%) vaccines. The pooled incidence proportion of SE (15 studies-2480 PwE) was 0.08% (95CI: 0.02%-0.32%, I 2 =0%), further subcategorized into the viral vector (0.00%, 95CI: 0.00%-1.00%, I 2 =0%), mRNA (0.09%, 95CI: 0.01%-0.62%, I 2 =0%), and inactivated (0.00%, 95CI: 0.00%-1.00%, I 2 =0%) vaccines. No significant difference was observed between mRNA and viral vector vaccines (5 studies, 1122 vs. 198 PwE, respectively) regarding increased seizure frequency (OR: 1.10, 95CI: 0.49-2.50, p-value=0.81, I 2 =0%). Significance: The meta-analysis proposed a 5% increased seizure frequency following COVID-19 vaccination in PwE, with no difference between mRNA and viral vector vaccines. Furthermore, we found a 0.08% incidence proportion for SE. While this safety evidence is noteworthy, this cost should be weighed against vaccination benefits.

  • Open Access

    Clinical potential of PD-1/PD-L1 blockade therapy for renal cell carcinoma (RCC): a rapidly evolving strategy

    by Mohammadsaleh Jahangir, Omid Yazdani, Mohammad Saeed Kahrizi, Sara Soltanzadeh, Hamidreza Javididashtbayaz, Azam Mivefroshan, Saba Ilkhani, Romina Esbati

    Programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) blockade therapy has become a game-changing therapeutic approach revolutionizing the treatment setting of human malignancies, such as renal cell carcinoma (RCC). Despite the remarkable clinical activity of anti-PD-1 or anti-PD-L1 monoclonal antibodies, only a small portion of patients exhibit a positive response to PD-1/PD-L1 blockade therapy, and the primary or acquired resistance might ultimately favor cancer development in patients with clinical responses. In light of this, recent reports have signified that the addition of other therapeutic modalities to PD-1/PD-L1 blockade therapy might improve clinical responses in advanced RCC patients. Until, combination therapy with PD-1/PD-L1 blockade therapy plus cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitor (ipilimumab) or various vascular endothelial growth factor receptors (VEGFRs) inhibitors axitinib, such as axitinib and cabozantinib, has been approved by the United States Food and Drug Administration (FDA) as first-line treatment for metastatic RCC. In the present review, we have focused on the therapeutic benefits of the PD-1/PD-L1 blockade therapy as a single agent or in combination with other conventional or innovative targeted therapies in RCC patients. We also offer a glimpse into the well-determined prognostic factor associated with the clinical response of RCC patients to PD-1/PD-L1 blockade therapy.


  • Open Access

    Fulminant psudeumonas pneumonia following coronary artery bypass grafting - Case report

    by Delaram Sakhaei, Ehsan Parvas, Saba Ilkhani, Seyed Hossein Ahmadi Tafti, Mana Jameie, Hossein Mohebbi

    Introduction and importance: Pneumonia has always been a source of complication after surgeries. Pseudomonas aeruginosa has emerged as one of the most problematic Gram-negative pathogens among nosocomial infections. Pneumonia caused by pseudomonas is usually slowly progressive allowing clinicians to detect and manage it on time. Clinical presentation: A 55-year-old man was hospitalized for elective CABG, complicated by fulminant pneumonia. Vancomycin and meropenem were adminestered as soon as the symptoms appeared. However, the patient died from septic shock syndrome caused by pseudomonas pneumonia on the third postoperative day, just hours after the first symptom appeared. The chest X-ray showed an extreme opacity within less than 12 h. Clinical discussion: This case is reported because of its rare clinical presentation of Fulminant pseudomonas pneumonia following cardiac surgery. Conclusion: Consider pseudomonas aeruginosa as a certain cause of pneumonia after cardiac surgery, and an organized, modified guideline is needed to determine the best option and timeline for treating this complication. Highlights:


  • Recent progress in cancer immunotherapy: Overview of current status and challenges

    by Mohammad Darvishi, Foad Tosan, Pooria Nakhaei, Danial Amiri Manjili, Sahar Afzali Kharkouei, Ali Alizadeh, Saba Ilkhani, Farima Khalafi, Firoozeh Abolhasani Zadeh, Seyyed-Ghavam Shafagh